The Medical Technology Directory

 Directory home | Search Directory | How to be listed in the Directory


Founded in 2001 in Ghent, Belgium, Ablynx [Euronext Brussels: ABLX] is a biopharmaceutical company focused on the discovery and development of Nanobodies(R), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases.

The Company currently has over 180 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007.

Ablynx is developing a portfolio of Nanobody(R)-based therapeutic programmes in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. Nanobodies(R) have been generated against more than 100 different disease targets.

Efficacy data has been obtained in 20 in vivo models for Nanobodies(R) against a range of different targets. Its lead programme, ALX-0081, a novel anti-thrombotic is in a multi-dose Phase 1b study in patients. ALX-0681, also a novel anti-thrombotic, is in advanced preclinical development.